Sri Lanka's First Insulin Factory Set to Begin Production by 2027, Backed by Rs. 3 Billion Investment

Sri Lanka is set to achieve a landmark milestone in its pharmaceutical sector, with the country's first dedicated insulin manufacturing facility expected to begin full production by 2027. The plant, established at an investment exceeding Rs. 3 billion, marks a significant step forward in the island nation's efforts to reduce its dependence on imported medicines and strengthen domestic healthcare capabilities.

A Historic Step for Sri Lanka's Pharmaceutical Industry

The establishment of a local insulin production facility has long been regarded as a critical need for Sri Lanka, given the growing burden of diabetes on the population. With tens of thousands of Sri Lankans relying on insulin to manage their condition, the country has historically been entirely dependent on foreign suppliers for this life-saving medication — a vulnerability that was starkly exposed during the economic crisis in recent years.

The new factory is expected to address this dependence directly, ensuring a more stable and affordable supply of insulin for patients across the country.

Investment and Timeline

The project represents one of the most substantial investments in Sri Lanka's local pharmaceutical manufacturing landscape, with the total capital outlay surpassing Rs. 3 billion. Authorities have indicated that production is targeted to commence in 2027, following the completion of necessary infrastructure development, equipment installation, and regulatory approvals.

Once operational, the facility is anticipated to not only serve domestic demand but potentially position Sri Lanka as a regional player in pharmaceutical manufacturing.

Reducing Import Dependency

Sri Lanka spends considerable foreign exchange annually on pharmaceutical imports, with insulin forming a notable portion of that expenditure. Local production is expected to ease pressure on the country's foreign reserves while simultaneously making insulin more accessible and affordable to patients, particularly those in lower-income brackets who rely on government healthcare services.

• Investment exceeds Rs. 3 billion
• Production targeted to begin in 2027
• Facility is Sri Lanka's first dedicated insulin manufacturing plant
• Expected to reduce foreign exchange spending on pharmaceutical imports

Significance for Public Health

Diabetes remains one of Sri Lanka's most pressing non-communicable disease challenges. Health experts have consistently highlighted the need for a reliable, locally produced insulin supply to safeguard patients against supply chain disruptions and price volatility in global markets.

The establishment of a domestic insulin production facility is not merely an industrial achievement — it is a public health imperative for a nation grappling with a rising diabetes epidemic.

As the 2027 production deadline approaches, the development of this facility will be closely watched by both the healthcare community and the broader business sector as a test case for Sri Lanka's ambitions in high-value pharmaceutical manufacturing.

Related Video